Header Ab 729

Imdusiran (AB-729)

Imdusiran is our RNAi therapeutic

Imdusiran is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen (HBsAg), which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. imdusiran targets hepatocytes using our novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology.

Clinical data to-date

Clinical data generated thus far has shown imdusiran to be generally safe and well-tolerated and to provide a robust and comparable decline in hepatitis B surface antigen and HBV DNA in patients regardless of dose, dosing interval or baseline characteristics. In addition, imdusiran continues to result in HBV-specific T-cell immune restoration and decrease of exhausted T-cells. Imdusiran is currently in multiple Phase 2a clinical trials in combination with other antiviral agents for the treatment of cHBV.

We believe imdusiran may have the following important advantages over other RNAi therapeutics and/or standard of care:

  • Less frequent dosing
  • Potential for shorter course therapy

Learn more about imdusiran in practice.